Posts

Empowering Sponsors with Compliant Data Collection and Integrity for a Variety of Clinical Studies | Jeeva Trials

Image
Traditional clinical guidelines, and stand-alone patient study and care pathways are proven to be increasingly inadequate, especially in a post-pandemic world with low clinical adherence, disrupted workflows, and stay-at-home orders.   Disrupted workflows means more time required to complete a study, fatigue of the research team, and wastage of resources. Researchers and study teams are increasingly adopting eClinical cloud trial tools that are designed to augment researchers, study teams and clinicians to augment their complex decision-making processes with targeted clinical knowledge, patient information and computerized clinical workflows. It directly improves the quality of clinical documentation. AI technologies provide the tool capabilities for drawing insights into data beyond what humans can. CROs (Contract Research Organizations) evaluate clinical study tools largely based on speed, flexibility and cost-efficiency. However, amidst these concerns, data integrity is not t...

Why Improving Diversity, Equity, and Inclusion in Clinical Trials should be a Research Priority? | Jeeva Trials

Image
Disparities related to diversity, equity, and inclusion (DEI) are common and well-known in clinical trials. It is well-documented that racial minorities, underprivileged, and non-white ethnic groups are much less represented in clinical trials . Historically, the numbers of clinical trial participants from diverse populations have not reflected real-world populations. Minorities often underrepresented in clinical trials include women, members of the LGBTQ+ community, indigenous populations, older adults, Native Americans, pediatric patients, and people living in hard-to-reach geographies. In the United States , socio-economic and geographic divides persistently limit patient diversity in clinical trials . As a result, we have only partial understanding of how safe and effective therapies are when they launch. Without diverse communities, researchers run the risk of making assumptions about drug safety and effectiveness that may not be accurate. There is a need to increase participat...

5 Ways by which SaaS Accelerates Clinical Trials Globally – Jeeva Trials

Image
The COVID-19 pandemic brought a new sense of appreciation for clinical trials as masses watched clinical trials closely while pharmaceutical companies raced against the clock to find viable vaccines and drugs for the Coronavirus outbreak with accuracy and unprecedented speed. But we also got a glimpse of how challenging clinical trial management can be for companies. This challenge brought a renewed sense of appreciation for human-centric software that streamlines the clinical trial process. For biopharmaceutical and medical device sponsors, CROs, or sites, adopting a software-as-a-service (SaaS) also comes with the benefit of flexible pricing. For example, systems like Jeeva offer a modular trial-fit subscription model with pay-per-module-user pricing. This means the trial’s capital expense can be managed as a predictable operating expense. The clinical trial cloud software market has grown as decentralized clinical trial management systems prove their worth as a silver lining of ...

Dealing with challenges in Quality Evidence Generation with a Real-Time Analytical Framework that makes Clinical Sense for Innovators

Image
Evidence linking interventions with health outcomes is vital for healthcare decision-making. Making sound choices about healthcare requires the best possible and quality evidence from clinical research. However, some of the decisions currently made during the drug development process are not supported by high-quality evidence.   As such, making informed decisions for allocating adequate resources to guide clinical Research development becomes challenging. At mid-stage clinical development , the challenge entails in determining the specific indication, if there are multiple potential indications. Moreover, evidence that is complete for some individuals or groups may be incomplete for others, leading to inefficiencies in decision-making. Evidence generation strategies are especially important at Phase III and Phase IV trials to allow for effective navigation through competitive and regulatory hurdles, while it may be difficult to effectively communicate potentially attractive pro...